17 unknown, 4 completed, 3 not yet recruiting, 2 active not recruiting. 25 Phase 2, 2 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 25 | Unknown 14, Completed 3, Not yet recruiting 3, Active not recruiting 2, Recruiting 2, Withdrawn 1 |
| Phase 1 | 2 | Completed 1, Unknown 1 |
| Phase 3 | 2 | Unknown 2 |
Follow Anlotinib: new trials by email Literature Review of Anlotinib trials Research Report on Anlotinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted Therapy Benmelstobart, SBRT, Anlotinib - Hepatocellular Carcinoma (HCC), First-line Targeted Therapy Failure | Phase 2 | Not yet recruiting | Nanfang Hospital, Southern Medical University | 29 | 2026-04-20 | 2026-04-17 |
| Tislelizumab Combined With Anlotinib and Nab-paclitaxel in II-III Resectable Non-small Cell Lung Cancer : A Prospective, Single-Arm, Phase II Study neoadjuvant therapy, Surgery, Adjuvant therapy - NSCLC, Tislelizumab | Phase 2 | Recruiting | Qilu Hospital of Shandong University | 34 | 2025-07-25 | 2026-10-13 |
| Neoadjuvant Therapy of Targeted Immunotherapy Combined With Chemotherapy for Locally Advanced HNSCC Benmelstobart, Anlotinib, Cisplatin - Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy | Phase 2 | Not yet recruiting | The First Affiliated Hospital with Nanjing Medical University | 45 | 2024-12-03 | 2024-11-21 |
| Anlotinib Hydrochloride Combined With Capeox in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer Anlotinib+Capeox, Capeox - Neoadjuvant Treatment, Rectal Cancer | Phase 2 | Withdrawn | Shanghai Minimally Invasive Surgery Center | 2023-11-01 | 2021-09-28 | |
| A Single Center, Single Arm Clinical Study on the Treatment of Advanced Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations and Failed EGFR TKIs With the Combination of Enrotinib and Paclitaxel Monoclonal Antibody Anlotinib, Penpulimab - Lung Cancer, TKI Resistance | Phase 3 | Unknown | Degan Lu | 52 | 2023-09-01 | 2023-09-21 |
| Safety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation With TP53 Co-Mutation Aumolertinib,Anlotinib - Aumolertinib, Anlotinib | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 47 | 2023-03-31 | 2023-03-21 |
| Anlotinib and Radiotherapy in Resectable Soft Tissue Sarcoma Anlotinib, Radiotherapy, Surgery - Soft Tissue Sarcoma, High Risk of Recurrence | Phase 2 | Unknown | Ruijin Hospital | 41 | 2022-11-01 | 2022-11-02 |
| Niraparib Plus Anlotinib for Recurrent Ovarian Cancer Niraparib plus anlotinib - Ovarian Carcinoma, Survival Outcomes | Phase 2 | Unknown | Lei Li | 36 | 2022-03-27 | 2022-04-13 |
| Anlotinib Combined With Platinum/Gemcitabine for First Line Treatment of Advanced Urothelial Carcinoma Anlotinib, Cisplatin, Carboplatin - Urothelial Carcinoma, Anlotinib | Phase 2 | Unknown | Tianjin Medical University Second Hospital | 53 | 2021-10-01 | 2021-09-01 |
| Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer Drug: Anlotinib, Drug: Carboplatin/Paclitaxel - Ovarian Neoplasms, Fallopian Tube Neoplasms | Phase 2 | Active not recruiting | Wenjun Cheng | 56 | 2021-08-24 | 2024-07-03 |
| Anlotinib Plus Anti-PD-1 Antibody AK105 for Advanced Pancreatic Cancer Anlotinib plus AK105 - Anlotinib, Anti-PD-1 Antibody | Phase 1 / Phase 2 | Unknown | Peking Union Medical College Hospital | 29 | 2021-05-12 | 2023-06-22 |
| Thermal Ablation Combined With Anlotinib and TQB2450 Solution for HCC Anlotinib and TQB2450 solution, TQB2450 solution - Hepatocellular Carcinoma, Thermal Ablation | Phase 3 | Unknown | Chinese PLA General Hospital | 80 | 2021-03-05 | 2021-03-04 |
| Neoadjuvant PD-1 Inhibitor (Sintilimab), Anlotinib Combined With Chemotherapy in Resectable Stage IIA-IIIB NSCLC Neoadjuvant therapy 1 - Sintilimab, Lung Cancer | Phase 2 | Active not recruiting | Tang-Du Hospital | 45 | 2021-03-01 | 2024-10-18 |
| SHR-1210 in Combination With Anlotinib in Patients With Advanced or Metastatic Esophageal Squamous Cell Cancer SHR-1210 plus Anlotinib - SHR-1210, Anlotinib | Phase 2 | Unknown | Peking Union Medical College Hospital | 33 | 2021-03-01 | 2021-03-15 |
| Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Anlotinib, Olaparib - Ovarian Cancer, Ovarian and Fallopian Tube Cysts and Neoplasms | Phase 2 | Unknown | Xiaoxiang Chen | 68 | 2020-10-28 | 2020-10-30 |
| Anlotinib Plus Sintilimab as First-line Treatment for Patients With Advanced Colorectal Cancer (APICAL-CRC) Anlotinib plus Sintilimab - Colorectal Cancer, Immunotherapy | Phase 2 | Completed | Shanghai Changzheng Hospital | 30 | 2020-06-01 | 2024-04-23 |
| Preoperative IMRT With Anlotinib and Penpulimab for Localized Sarcoma （SPARE-01） Anlotinib hydrochloride - Sarcoma,Soft Tissue, Extremity | Phase 2 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 30 | 2020-05-01 | 2026-06-04 |
| Anlotinib Combined With TACE in Hepatocellular Carcinoma Patients at High Risk of Post Surgery Recurrence Anlotinib Hydrochloride, TACE - Hepatocellular Carcinoma, TACE | Phase 2 | Unknown | First Affiliated Hospital Xi'an Jiaotong University | 30 | 2020-04-23 | 2023-01-17 |
| Anlotinib In Combination With Durvalumab As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study Anlotinib In Combination With Durvalumab - Anlotinib, Durvalumab | Phase 2 | Unknown | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 33 | 2020-04-01 | 2020-03-19 |
| Anlotinib In Combination With PD-1/L1 Inhibitor As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study Anlotinib In Combination With PD-1/L1 Inhibitor - NSCLC, Anlotinib | Phase 2 | Unknown | Xiaorong Dong | 33 | 2020-04-01 | 2020-03-18 |
Showing 20 of 29. Sign in to see all of them.
Carcinoma, Hepatocellular (3) · Lung Neoplasms (3) · Ovarian Neoplasms (3) · Carcinoma (2) · Carcinoma, Ovarian Epithelial (2) · Genital Diseases, Female (2) · Genital Neoplasms, Female (2) · Neoplasms by Histologic Type (2) · Neoplasms by Site (2) · Neoplasms, Glandular and Epithelial (2) · Ovarian Diseases (2) · Sarcoma (2) · Small Cell Lung Carcinoma (2) · Urogenital Neoplasms (2) · Adnexal Diseases (1)
Neoplasms (19) · Neoplasms by Site (16) · Neoplasms by Histologic Type (7) · Digestive System Diseases (6) · Digestive System Neoplasms (6) · Lung Diseases (6) · Respiratory Tract Diseases (6) · Respiratory Tract Neoplasms (6) · Thoracic Neoplasms (6) · Carcinoma (5) · Neoplasms, Glandular and Epithelial (5) · Female Urogenital Diseases (4) · Female Urogenital Diseases and Pregnancy Complications (4) · Urogenital Diseases (4) · Adenocarcinoma (3)
anlotinib (22) · sintilimab (3) · Carboplatin (2) · Cisplatin (2) · Drug Therapy (2) · Surgical Procedures, Operative (2) · CP protocol (1) · Chemotherapy, Adjuvant (1) · Docetaxel (1) · Etoposide (1) · Gemcitabine (1) · Irinotecan (1) · Neoadjuvant Therapy (1) · Paclitaxel (1) · Pemetrexed (1)
Peking Union Medical College Hospital (2) · Shanghai Changzheng Hospital (2) · Baodong Qin (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) · Chinese PLA General Hospital (1) · Degan Lu (1) · First Affiliated Hospital Xi'an Jiaotong University (1) · First People's Hospital of Hangzhou (1) · Lei Li (1) · Nanfang Hospital, Southern Medical University (1) · Peng Yuan (1) · Qilu Hospital of Shandong University (1) · Ruijin Hospital (1) · Shanghai Chest Hospital (1)
China (23)
Baohui Han (1) · Chen Jinzhang (1) · Lei Li, M.D. (1) · Peng Yuan (1) · Wenjun Cheng, MD,PhD (1) · Xiaoxiang Chen, MD,PhD (1) · You Lu, MD (1) · Yuanjie Niu, MD,PhD (1) · Yuhui Shen, MD (1) · Zheng Wu, PhD (1) · Zhiming Li (1)
PMID 27413711, PMID 28486985, PMID 29438373, PMID 30419091, PMID 33433946, PMID 33791214, PMID 34327136, PMID 35623069, PMID 35875118, PMID 36116169, PMID 36749752, PMID 39465257, PMID 40555062, PMID 40954146, PMID 41484570